DAF
0.016
60%
ATC
0.001
-50%
FAU
0.009
50%
ARV
0.003
-25%
M2M
0.009
50%
CHM
0.015
-25%
DXN
0.39
41.8%
EPN
0.022
-24.1%
NXL
1.915
34.4%
RWL
0.15
-21.1%
ARO
0.004
33.3%
ERE
0.012
-20%
C7A
0.004
33.3%
FIN
0.004
-20%
RKB
0.004
33.3%
KGN
3.67
-18.6%
ABE
0.027
28.6%
IRD
0.009
-18.2%
AUQ
0.047
27%
SP3
0.009
-18.2%
PKY
0.043
26.5%
CDE
0.005
-16.7%
ACU
0.13
23.8%
ENL
0.005
-16.7%
AXN
0.033
22.2%
RLG
0.005
-16.7%
COY
0.006
20%
WIN
0.015
-16.7%
ECS
0.006
20%
ALM
0.011
-15.4%
ESR
0.036
20%
AEV
0.006
-14.3%
GTN
0.24
20%
CRR
0.006
-14.3%
RGL
0.012
20%
UNT
0.006
-14.3%
WRX
0.024
20%
HMG
0.225
-13.5%
ZEU
0.006
20%
NPM
0.013
-13.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NTI Completed patient recruitment for its clinical trial for children with Autism

Neurotech International (ASX:NTI) completed patient recruitment for its Phase II/III NTIASD2 clinical trial for children with Autism. Patients recruited require substantial support and very substantial support autism | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231219/pdf/05yq6fqpsynsvp.pdf #Autism #shorts